TUR-006

TUR-006 is a small molecule dihydrofolate reductase (DHFR) inhibitor originally developed by Vyera Pharmaceuticals for the treatment of infectious diseases. As a DHFR inhibitor, the compound works by blocking the enzyme responsible for converting dihydrofolate into tetrahydrofolate, a crucial step in the synthesis of nucleic acids and proteins. This inhibition effectively halts DNA synthesis and cell division within targeted pathogens. While the drug was positioned for infectious disease indications, its specific clinical development progress remains limited, with its current global R&D status categorized as pending.

Brand names

Fanotaprim